A Phase 3, Randomized, Double-blind, Double-dummy, Parallel-group, Active Drug and Placebo-controlled, Safety, Efficacy and Superiority of Sibutramine IR/Topiramate XR in Overweight Adults With Comorbidities/Obesity

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sibutramine/topiramate (Primary) ; Sibutramine; Topiramate
Indications Obesity
Focus Registrational; Therapeutic Use
Acronyms UNLIMITED
Sponsors Eurofarma

Most Recent Events

14 Feb 2025 Planned End Date changed from 30 Jul 2027 to 1 Mar 2028.
14 Feb 2025 Planned primary completion date changed from 30 Mar 2027 to 1 Mar 2028.
14 Feb 2025 Planned initiation date changed from 30 Oct 2025 to 1 Apr 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight